The immunological landscape of glioma is influenced by IDH1/2 mutations; indeed, in mutated tumors PD-L1 is significantly diminished supporting the rationale of ICi treatment in IDH1/2wt patients (52). The gene discussed is IDH1; the disease is glioma.